Opioid Maintenance, Weaning and Detoxification Techniques; Where We have been, Where We are Now and What the Future Holds: An Update

References

• Centers for Disease Control and Prevention . CDC WONDER (2017). http://wonder.cdc.gov
   Google Scholar
• Van Zee A . The promotion and marketing of OxyContin: commercial triumph, public health tragedy. Am. J. Public Health99(2), 221–227 (2009).
   PubMed Web of Science ®Google Scholar
• Berry P , DahlJL , DonovanMIet al. Improving the Quality of Pain Management Through Measurement and Action. Joint Commission on Accreditation of Healthcare Organizations, Oakbrook Terrace, IL, USA. (2003).
   Google Scholar
• Centers for Disease Control and Prevention . Understanding the epidemic. Opioid Overdose (2017). www.cdc.gov/drugoverdose/epidemic/index.html
   Google Scholar
• Hedegaard H , WarnerM , MiniñoAM. Drug overdose deaths in the United States, 1999–2016. Data Briefs (2017). www.cdc.gov/nchs/products/databriefs/db294.htm
   Google Scholar
• Dowell D , HaegerichTM , ChouR. CDC guideline for prescribing opioids for chronic pain – United States, 2016. JAMA315(15), 1624–1645 (2016).
   PubMed Web of Science ®Google Scholar
• North Carolina General Assembly . Strengthen Opioid Misuse Prevention (STOP) Act overview. (2017). www.ncleg.net/DocumentSites/Committees/NCCFTF/Presentations/2017-2018/STOP%20Act%20Overview%20CFTF%209-26-2017.pdf
   Google Scholar
• US FDA . Information about medication assisted treatment. Drugs (2018). www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm600092.htm
   Google Scholar
• Felberbaum M . FDA approves the first non-opioid treatment for management of opioid withdrawal symptoms in adults. FDA News Rel. (2018). www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm607884.htm
   Google Scholar
• Lucemyra, prescribing information. US Worldmeds, KY, USA (2018).
   Google Scholar
• Electronic Code of Federal Regulations . Title 42: public health (2018). https://ecfr.io/Title-42/pt42.1.8#sp42.1.8.f
   Google Scholar
• Smith NW . Federal Guidelines for Opioid Treatment Programs. Substance Abuse and Mental Health Services Administration, WA, DC, USA (2015).
   Google Scholar
• Dumas EO , PollackGM. Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective. AAPS J.10(4), 537–551 (2008).
   PubMed Web of Science ®Google Scholar
• Rothman RB , LongJB , BykovVet al. Upregulation of the opioid receptor complex by the chronic administration of morphine: a biochemical marker related to the development of tolerance and dependence. Peptides12(1), 151–160 (1991).
   PubMed Web of Science ®Google Scholar
• Tao P , ChangL , ChouY , LawP , LohHH. Chronic opioid treatment may uncouple opioid receptors and G-proteins: evidence from radiation inactivation analysis. Eur. J. Pharmacol.246(3), 233–238 (1993).
   PubMed Web of Science ®Google Scholar
• Angres DH , Bettinardi-AngresK. The disease of addiction: origins, treatment, and recovery. Dis. Mon.54(10), 696–721 (2008).
   PubMed Web of Science ®Google Scholar
• Fishman SM , BallantyneJC , RathmellJP. Bonica’s Management of Pain (4) Fishman SM, Ballantyne JC, Rathmell JP (eds). Lippincott Williams & Wilkins, MD, USA. (2010).
   Google Scholar
• Cicero TJ , InciardiJA , MuñozA. Trends in abuse of OxyContin and other opioid analgesics in the United States: 2002–2004. J. Pain6(10), 662–672 (2005).
   PubMed Web of Science ®Google Scholar
• Clark JD . Chronic pain prevalence and analgesic prescribing in a general medical population. J. Pain Symptom Manage.23(2), 131–137 (2002).
   PubMed Web of Science ®Google Scholar
• Michna E , RossEL , HynesWLet al. Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. J. Pain Symptom Manage.28(3), 250–258 (2004).
   PubMed Web of Science ®Google Scholar
• Kupfer DJ, Reigier DA, Narrow WE, Schultz SK, Kuhl EA. Diagnostic and Statistical Manual of Mental Disorders (5). American Psychiatric Association, WA, DC, USA. (2013).
   Google Scholar
• Day E , StrangJ. Outpatient versus inpatient opioid detoxification: a randomized controlled trial. J. Subst. Abuse Treat.40(1), 56–66 (2011).
   PubMed Web of Science ®Google Scholar
• Zhu H , WuL. National trends and characteristics of inpatient detoxification for drug use disorders in the United States. BMC Public Health18(1), 1073–1087 (2018).
   PubMed Web of Science ®Google Scholar
• Nosyk B , LiL , EvansEet al. Utilization and outcomes of detoxification and maintenance treatment for opioid dependence in publicly-funded facilities in California, USA: 1991–2012. Drug Alcohol Depend.143, 149–157 (2014).
   PubMed Web of Science ®Google Scholar
• Torrens M , CastilloC , SanL , DelMoral E , GonzálezML , DeLa Torre R. Plasma methadone concentrations as an indicator of opioid withdrawal symptoms and heroin use in a methadone maintenance program. Drug Alcohol Depend.52(3), 193–200 (1998).
   PubMed Web of Science ®Google Scholar
• Dijkstra BA , KrabbePF , DeJong CA , VanDer Staak CP. Prediction of withdrawal symptoms during opioid detoxification. J. Opioid Manag.4(5), 311–319 (2008).
   PubMedGoogle Scholar
• Margolin A , KostenTR , MillerNS. Opioid detoxification and maintenance with blocking agents. In: Comprehensive Handbook of Drug and Alcohol Addiction..Taylor & Francis, London, UK, 1201–1212 (1991).
   Google Scholar
• Mattick RP , HallW. Are detoxification programmes effective?Lancet347(8994), 97–100 (1996).
   PubMed Web of Science ®Google Scholar
• Institute of Medicine (US) Committee for the substance abuse coverage study. In: Treating Drug Problems: A Study of the Evolution, Effectiveness, and Financing of Public and Private Drug Treatment Systems.National Academies Press, WA, DC, USA (1990).
   Google Scholar
• Gowing LR , AliRL , WhiteJM. The management of opioid withdrawal. Drug and Alcohol Rev.19(3), 309–318 (2000).
   Web of Science ®Google Scholar
• Cuskey WR , ChambersCD , WielandWF. Predicting attrition during the outpatient detoxification of narcotic addicts. Med. Care9, 108–116 (1971).
   PubMedGoogle Scholar
• Warden D , SubramaniamGA , CarmodyTet al. Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth. Addict. Behav.37(9), 1046–1053 (2012).
   PubMed Web of Science ®Google Scholar
• Ahmed S , CreangaAA , GillespieDG , TsuiAO. Economic status, education and empowerment: implications for maternal health service utilization in developing countries. PLoS ONE5(6), e11190 (2010).
   PubMed Web of Science ®Google Scholar
• Joseph H , StancliffS , LangrodJ. Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt. Sinai J. Med.67(5-6), 347–364 (2000).
   PubMed Web of Science ®Google Scholar
• Kampman K , JarvisM. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J. Addict. Med.9(5), 358–367 (2015).
   PubMed Web of Science ®Google Scholar
• Faggiano F , Vigna-TagliantiF , VersinoE , LemmaP. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst. Rev. (3), 1–38 (2003).
   Google Scholar
• Donny EC , BrasserSM , BigelowGE , StitzerML , WalshSL. Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self‐administration in opioid‐dependent volunteers. Addiction100(10), 1496–1509 (2005).
   PubMed Web of Science ®Google Scholar
• Sordo L , BarrioG , BravoMJet al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ357, 1–14 (2017).
   Google Scholar
• Vogel M , DürstelerKM , WalterM , HerdenerM , NordtC. Rethinking retention in treatment of opioid dependence – the eye of the beholder. Int. J. Drug Policy39, 109–113 (2017).
   PubMed Web of Science ®Google Scholar
• Christie JM . Opioid prescribing: methadone risk mitigation. APSF Newsletter26(1), 1–15 (2011).
   Google Scholar
• Pani PP , TroguE , MaremmaniI , PaciniM. QTc interval screening for cardiac risk in methadone treatment of opioid dependence. Cochrane Database Syst. Rev.6, CD008939 (2013).
   PubMed Web of Science ®Google Scholar
• Connery HS . Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv. Rev. Psychiatry23(2), 63–75 (2015).
   PubMed Web of Science ®Google Scholar
• Walton G , NolanS , SutherlandC , AhamadK. Sustained release oral morphine as an alternative to methadone for the treatment of opioid-use disorder post Torsades de Pointes cardiac arrest. BMJCase Rep.2015, bcr2015210239 (2015).
   Google Scholar
• Hammig R , KohlerW , Bonorden-KleijKet al. Safety and tolerability of slow-release oral morphine versus methadone in the treatment of opioid dependence. J. Subst. Abuse Treat.47(4), 275–281 (2014).
   PubMed Web of Science ®Google Scholar
• Mitchell TB , WhiteJM , SomogyiAA , BochnerF. Slow‐release oral morphine versus methadone: a crossover comparison of patient outcomes and acceptability as maintenance pharmacotherapies for opioid dependence. Addiction99(8), 940–945 (2004).
   PubMed Web of Science ®Google Scholar
• Eder H , JagschR , KraigherD , PrimoracA , EbnerN , FischerG. Comparative study of the effectiveness of slow‐release morphine and methadone for opioid maintenance therapy. Addiction100(8), 1101–1109 (2005).
   PubMed Web of Science ®Google Scholar
• Beck T , HaasenC , VertheinUet al. Maintenance treatment for opioid dependence with slow‐release oral morphine: a randomized cross‐over, non‐inferiority study versus methadone. Addiction109(4), 617–626 (2013).
   Web of Science ®Google Scholar
• Freedman RR , CzertkoG. A comparison of thrice weekly LAAM and daily methadone in employed heroin addicts. Drug Alcohol Depend.8(3), 215–222 (1981).
   PubMed Web of Science ®Google Scholar
• Clark NC , LintzerisN , GijsbersAet al. LAAM maintenance vs methadone maintenance for heroin dependence. Cochrane Database Syst. Rev. (2), CD002210. ( 2002).
   Google Scholar
• Kux L . Determination that ORLAAM (levomethadyl acetate hydrochloride) oral solution, 10 milligrams/milliliter, was not withdrawn from sale for reasons of safety or effectiveness. US FDA, WA, DC, USA (2011).
   Google Scholar
• Johnson RE , ConeEJ , HenningfieldJE , FudalaPJ. Use of buprenorphine in the treatment of opiate addiction I: physiologic and behavioral effects during a rapid dose induction. Clin. Pharmacol. Ther.46(3), 335–342 (1989).
   PubMed Web of Science ®Google Scholar
• Bickel WK , AmassL. Buprenorphine treatment of opioid dependence: a review. Exp. Clin. Psychopharmacol.3(4), 477–489 (1995).
   Web of Science ®Google Scholar
• Strain EC , StitzerML , LiebsonIA , BigelowGE. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am. J. Psychiatry151(7), 1025–1030 (1994).
   PubMed Web of Science ®Google Scholar
• Ling WW , CharuvastraC , CollinsJFet al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction93(4), 475–486 (1998).
   PubMed Web of Science ®Google Scholar
• Fudala PJ , JaffeJH , DaxEM , JohnsonRE. Use of buprenorphine in the treatment of opioid addiction II: physiologic and behavioral effects of daily and alternate‐day administration and abrupt withdrawal. Clin. Pharmacol. Ther.47(4), 525–534 (1990).
   PubMed Web of Science ®Google Scholar
• Gowing L , AliR , WhiteJM , MbeweD. Buprenorphine for managing opioid withdrawal. Cochrane Database Syst. Rev.2, CD002025 (2017).
   Web of Science ®Google Scholar
• Petry NM , BickelWK , BadgerGJ. A comparison of four buprenorphine dosing regimens in the treatment of opioid dependence. Clin. Pharmacol. Ther.66(3), 306–314 (1999).
   PubMed Web of Science ®Google Scholar
• Ling WW , AmassL , ShoptawSet al. A multi‐center randomized trial of buprenorphine–naloxone versus clonidine for opioid, detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction100(8), 1090–1100 (2005).
   PubMed Web of Science ®Google Scholar
• Mattick RP , BreenC , KimberJ , DavoliM. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst. Rev.2, CD002207 (2014).
   PubMed Web of Science ®Google Scholar
• Bruneau J , AhamadK , GoyerMEet al. Management of opioid use disorders: a national clinical practice guideline. CMAJ190(9), E247–E257 (2018).
   PubMed Web of Science ®Google Scholar
• Schuckit MA . Treatment of opioid-use disorders. N. Engl. J. Med.375(4), 357–368 (2016).
   PubMed Web of Science ®Google Scholar
• Bell J . Pharmacological maintenance treatments of opiate addiction. Br. J. Clin. Pharmacol.77(2), 253–263 (2014).
   PubMed Web of Science ®Google Scholar
• Peddicord S . FDA approves first buprenorphine implant for treatment of opioid dependence. FDA News Rel. (2016). www.fda.gov/newsevents/newsroom/pressannouncements/ucm503719.htm
   Google Scholar
• Titan Pharmaceuticals, Inc., Probuphine . Product Pipeline (2018). www.titanpharm.com/pipeline/probuphine
   Google Scholar
• Itzoe M , GuarnieriM. New developments in managing opioid addiction: impact of a subdermal buprenorphine implant. Drug Des. Devel. Ther.11, 1429–1437 (2017).
   PubMed Web of Science ®Google Scholar
• Felberbaum M . FDA approves first once-monthly buprenorphine injection, a medication-assisted treatment option for opiod use disorder. FDA News Rel. (2017). www.fda.gov/newsevents/newsroom/pressannouncements/ucm587312.htm
   Google Scholar
• Sublocade, prescribing information. Indivior, Inc. VA, USA (2017).
   Google Scholar
• Rosenthal RN , GoradiaVV. Advances in the delivery of buprenorphine for opioid dependence. Drug Des. Devel. Ther.11, 2493–2505 (2017).
   PubMed Web of Science ®Google Scholar
• Seth P , SchollL , RuddRA , BaconS. Overdose deaths involving opioids, cocaine, and psychostimulants – United States, 2015–2016. MMWR67(12), 349–358 (2018).
   PubMed Web of Science ®Google Scholar
• Wheeler E , DavidsonPJ , JonesTS , IrwinKS. Community-based opioid overdose prevention programs providing naloxone – United States, 2010. MMWR61(6), 101–105 (2012).
   PubMedGoogle Scholar
• Raffa RB , TaylorR , PergolizziJV , NalamachuS , EdwardsES , EdwardsET. Application of human factors engineering (HFE) to the design of a naloxone auto-injector for the treatment of opioid emergencies. Drug Deliv. Transl. Res.7(1), 1–10 (2016).
   Web of Science ®Google Scholar
• Rando J , BroeringD , OlsonJE , MarcoC , EvansSB. Intranasal naloxone administration by police first responders is associated with decreased opioid overdose deaths. Am. J. Emerg. Med.33(9), 1201–1204 (2015).
   PubMed Web of Science ®Google Scholar
• Kim D , IrwinKS , KhoshnoodK. Expanded access to naloxone: options for critical response to the epidemic of opioid overdose mortality. Am. J. Public Health99(3), 402–407 (2009).
   PubMed Web of Science ®Google Scholar
• Kjome KL , MoellerFG. Long-acting injectable naltrexone for the management of patients with opioid dependence. Subst. Abuse5, 1–9 (2011).
   PubMedGoogle Scholar
• Gowing L , FarrellM , AliR , WhiteJM. α2‐adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst. Rev. (2), CD002024 (2016).
   Google Scholar
• Gowing L , AliR , WhiteJM. Opioid antagonists with minimal sedation for opioid withdrawal. Cochrane Database Syst. Rev. (5), CD002021 (2017).
   Web of Science ®Google Scholar
• Gold CG , CullenDJ , GonzalesS , HoutmeyersD , DwyerMJ. Rapid opioid detoxification during general anesthesia: a review of 20 patients. Anesthesiology91(6), 1639 (1999).
   PubMed Web of Science ®Google Scholar
• Resnick RB , KestenbaumRS , WashtonA , PooleD. Naloxone-precipitated withdrawal: a method for rapid induction onto naltrexone. Clin. Pharmacol. Ther.21(4), 409–413 (1977).
   PubMed Web of Science ®Google Scholar
• Cucchia AT , MonnatM , SpagnoliJ , FerreroF , BertschyG. Ultra-rapid opiate detoxification using deep sedation with oral midazolam: short and long-term results. Drug Alcohol Depend.52(3), 243–250 (1998).
   PubMed Web of Science ®Google Scholar
• Pfab R , HirtlC , ZilkerT. Opiate detoxification under anesthesia: no apparent benefit but suppression of thyroid hormones and risk of pulmonary and renal failure. J. Toxicol. Clin Toxicol.37(1), 43–50 (1999).
   PubMed Web of Science ®Google Scholar
• Collins ED , KleberHD , WhittingtonRA. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial. JAMA294(8), 903–913 (2005).
   PubMed Web of Science ®Google Scholar
• Berlin D , FarmerBM , RaoRBet al. Deaths and severe adverse events associated with anesthesia-assisted rapid opioid detoxification – New York City, 2012. MMWR62(38), 777–780 (2013).
   PubMed Web of Science ®Google Scholar
• Davoli M , FarrellM , FiellinDet al. Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. WHO, Switzerland (2009).
   Google Scholar
• Gerada C , PillingS , BissettPet al. Drug Misuse: Opiod Detoxification. British Psychological Society, Leicester, UK (2008).
   Google Scholar